These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27854508)

  • 21. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.
    Sloan DJ; Lewis JM
    Trans R Soc Trop Med Hyg; 2016 Mar; 110(3):163-72. PubMed ID: 26884496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children.
    Schaaf HS; Garcia-Prats AJ; McKenna L; Seddon JA
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):233-244. PubMed ID: 29280409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations for treating children with drug-resistant tuberculosis.
    Galli L; Lancella L; Garazzino S; Tadolini M; Matteelli A; Migliori GB; Principi N; Villani A; Esposito S;
    Pharmacol Res; 2016 Mar; 105():176-82. PubMed ID: 26821118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
    Mukherjee A; Lodha R; Kabra SK
    Expert Opin Pharmacother; 2017 Oct; 18(15):1595-1606. PubMed ID: 28847228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
    J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.
    McAnaw SE; Hesseling AC; Seddon JA; Dooley KE; Garcia-Prats AJ; Kim S; Jenkins HE; Schaaf HS; Sterling TR; Horsburgh CR
    Int J Infect Dis; 2017 Mar; 56():194-199. PubMed ID: 27955992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
    Buziashvili M; Davtyan H; Sereda Y; Denisiuk O; Gozalov O; Lomtadze N; Hovhannesyan A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis.
    Yao G; Zhu M; Nie Q; Chen N; Tu S; Zhou Y; Xiao F; Liu Y; Li X; Chen H
    J Int Med Res; 2023 Jan; 51(1):3000605221148416. PubMed ID: 36719280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case series of multidrug-resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country.
    Babar ZU; Nasim A; Kumar S; Nazmi J; Badlani S; Nadeem A; Aziz T
    Transpl Infect Dis; 2021 Aug; 23(4):e13659. PubMed ID: 34057810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of recent advances in anti-tubercular drug development.
    Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
    Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of patients with multidrug-resistant tuberculosis.
    Lange C; Aarnoutse RE; Alffenaar JWC; Bothamley G; Brinkmann F; Costa J; Chesov D; van Crevel R; Dedicoat M; Dominguez J; Duarte R; Grobbel HP; Günther G; Guglielmetti L; Heyckendorf J; Kay AW; Kirakosyan O; Kirk O; Koczulla RA; Kudriashov GG; Kuksa L; van Leth F; Magis-Escurra C; Mandalakas AM; Molina-Moya B; Peloquin CA; Reimann M; Rumetshofer R; Schaaf HS; Schön T; Tiberi S; Valda J; Yablonskii PK; Dheda K
    Int J Tuberc Lung Dis; 2019 Jun; 23(6):645-662. PubMed ID: 31315696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
    Pecora F; Dal Canto G; Veronese P; Esposito S
    Microorganisms; 2021 May; 9(5):. PubMed ID: 34067732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.